Captopril and nifedipine in combination for moderate to severe essential hypertension.
- 1 June 1987
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 9 (6) , 629-633
- https://doi.org/10.1161/01.hyp.9.6.629
Abstract
The effects of the addition of a calcium entry antagonist, nifedipine (20-mg tablet twice a day), to an angiotensin converting enzyme inhibitor, captopril (25 mg three times a day), and the addition of captopril to nifedipine were observed in two separate studies in patients with essential hypertension. After 4 weeks of captopril therapy alone, mean arterial pressure fell by 12 mm Hg, and with the addition of nifedipine to captopril for a further month, blood pressure fell by an additional 10 mm Hg. In a separate group of patients treated with the same doses, mean arterial pressure fell by 17 mm Hg with nifedipine treatment alone; when captopril was added to the nifedipine therapy for an additional month, mean arterial pressure fell by a further 11 mm Hg. These blood pressures were measured 2 hours after the last dose; however, there was less of a fall in blood pressure when it was measured 12 hours after the last dose. This study confirms that captopril and nifedipine have a marked additive effect on blood pressure in whichever order they are given, but it shows that the combination is relatively short-acting.This publication has 5 references indexed in Scilit:
- CaptoprilJournal of Cardiovascular Pharmacology, 1985
- Antihypertensive Treatment Using Calcium Antagonists in Combination with Captopril Rather than DiureticsJournal of Cardiovascular Pharmacology, 1985
- Effect of Chronic Nifedipine in Patients Inadequately Controlled by a Converting Enzyme Inhibitor and a DiureticJournal of Cardiovascular Pharmacology, 1985
- Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockadeAmerican Heart Journal, 1978
- Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in ManNew England Journal of Medicine, 1978